Back to search

The Open University

Discovery of Novel Hub Genes Across Breast, Ovarian, and Prostate Cancers

Abstract

dc:description.abstract

Breast, ovarian, and prostate cancers are amongst the most prevalent diagnosed cancers annually. These cancers are classified into subtypes based on specific characteristics, however, there are some common underlying aetiological features such as hormone receptors. Few studies have investigated such common features. Here, breast, ovarian and prostate cancers were analysed to identify cross-cancer gene/s that could potentially be used as biomarkers and/or treatment targets. A novel method/workflow using R programming was developed to integrate publicly available microarray tissue (RNA) data to increase sensitivity/sample numbers. <br></br><br></br> Significantly upregulated differentially expressed genes (DEGs) that were identified, were compared between the three cancers using classifications identified in literature. Two analyses were conducted comparing subtypes: 1) histological breast cancer, ovarian cancer tissue location, and prostate cancer Gleason grade group; 2) breast cancer molecular, ovarian epithelial, and prostate cancer Gleason score. Three cross-cancer significantly upregulated DEGs, <i>HMMR, CENPE</i>, and <i>STIL</i> were identified in both analyses: 1) <i>HMMR</i> Log2FC = 1.37 (P = 1.29E-10), <i>CENPE</i> Log2FC = 1.12 (P = 6.62E-08), and <i>STIL</i> Log2FC = 1.07 (P = 4.38E-08); 2) <i>HMMR</i> Log2FC = 1.64 (P = 2.23E-04), <i>CENPE</i> Log2FC = 1.42 (P = 5.82E-05), <i>STIL</i> Log2FC = 1.35 (P = 7.82E-06). <br></br><br></br> <i>HMMR, CENPE</i>, and <i>STIL</i> were significantly associated with reduced survival times (using 95% confidence interval) in recurrence free survival (Hazard Ratio (HR) = 1.18 - 1.84, P = 1E-16 - 0.012), and in overall survival (HR = 1.29 - 2.10, P = 7.1E-03 - 5.2E-09). <br></br><br></br> Network analysis identified <i>HMMR, CENPE</i>, and <i>STIL</i> as hub genes. Gene ontology (GO) and literature search identified them as functioning in G2/M phase cell cycle transition, indicating a shared mechanism/s of action. Therefore, the hub genes (<i>HMMR, CENPE, STIL</i>) termed ‘HCS three-gene signature’ were identified as potential biomarkers and treatment targets in breast, ovarian, or prostate cancers, regardless of subtype.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
The Open University
Year dc:date.issued
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chandler, Stephen

Rights

Language dc:language
en

Chain of custody

source
Harvested from
The Open University
Base URL
oro.open.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Chandler, Stephen. Discovery of Novel Hub Genes Across Breast, Ovarian, and Prostate Cancers. doctoral thesis, The Open University, 2022.